Targeting Amyloid Beta Aggregation and Neuroinflammation in Alzheimer’s Disease: Advances and Future Directions

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia in the elderly. Among the diverse pathological features of AD, amyloid beta (Aβ) aggregation and neuroinflammation are recognized as central and interlinked mechanisms driving disease progression. This review focuses specifically on these two processes and highlights current pharmacological limitations in modifying disease pathology. Natural products such as curcumin, resveratrol, Ginkgo biloba, epigallocatechin gallate (EGCG), crocin, ashwagandha, and cannabidiol (CBD) have shown promising activity in modulating Aβ aggregation and neuroinflammatory pathways, offering multi-target neuroprotective effects in preclinical studies. However, their therapeutic application remains hindered by poor solubility, instability, rapid metabolism, and limited blood–brain barrier (BBB) permeability. To overcome these barriers, nanotechnology-based drug delivery systems—including polymeric nanoparticles, niosomes, solid lipid nanoparticles, and chitosan-based carriers—have emerged as effective strategies to enhance brain targeting, bioavailability, and pharmacological efficacy. We summarize the mechanistic insights and nanomedicine approaches related to these bioactives and discuss their potential in developing future disease-modifying therapies. By focusing on Aβ aggregation and neuroinflammation, this review provides a targeted perspective on the evolving role of natural compounds and nanocarriers in AD treatment.

• Publication year

  2026

• Venue

  Cells

• Publication date

  2026-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/cells15030295PMID 41677657PMCID 12897309
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence

  2025cited by this paper
• Early microglial and astrocyte reactivity in preclinical Alzheimer's disease

  2025cited by this paper
• Investigating the Effects of Niosome Curcumin on the Alteration of NF-κB Gene Expression and Memory and Learning in the Prefrontal Cortex of Alzheimer’s Rats

  2025cited by this paper
• Potential Applications of Natural Components of Traditional Chinese Medicine Delivery via Nanoparticle Drug Delivery Systems in the Treatment of Alzheimer’s Disease

  2025cited by this paper
• Cannabidiolic Acid Rescues Deficits in Hippocampal Long-Term Potentiation in Models of Alzheimer’s Disease: An Electrophysiological and Proteomic Analysis

  2025cited by this paper
• Cannabidiol as a multifaceted therapeutic agent: mitigating Alzheimer's disease pathology and enhancing cognitive function

  2025cited by this paper
• A comprehensive review on the bioactivity and pharmacological attributes of Withania somnifera.

  2025cited by this paper
• From Mood to Memory: Unlocking Saffron’s Potential in Brain Health

  2025cited by this paper
• Intranasal resveratrol delivery to the brain with chitosan-decorated bovine serum albumin nanoparticles: Advancing Alzheimer's management in old female rats through QbD-based optimization, in vitro evaluation, and in vivo exploration.

  2025cited by this paper
• Engineered nanoparticles for the treatment of Alzheimer’s disease

  2025cited by this paper
• Effect of epigallocatechin-3-gallate (EGCG) on cognitive functioning and the expression of APP and BDNF in the hippocampus of rats with streptozotocin -induced Alzheimer-like disease

  2025cited by this paper
• Synergistic activity of nootropic herbs as potent therapeutics for Alzheimer's disease: A cheminformatics, pharmacokinetics, and system pharmacology approach

  2024cited by this paper
• Withania somnifera (Ashwagandha) Improves Spatial Memory, Anxiety and Depressive-like Behavior in the 5xFAD Mouse Model of Alzheimer’s Disease

  2024cited by this paper
• Epigallocatechin-3-Gallate Inhibits Oxidative Stress Through the Keap1/Nrf2 Signaling Pathway to Improve Alzheimer Disease

  2024cited by this paper
• Updates in Alzheimer's disease: from basic research to diagnosis and therapies

  2024cited by this paper
• Cannabidiol and Alzheimer's disease.

  2024cited by this paper
• Epigallocatechin-3-gallate Inhibits LPS/AβO-induced Neuroinflammation in BV2 Cells through Regulating the ROS/TXNIP/NLRP3 Pathway

  2024cited by this paper
• Ginkgo biloba: A Leaf of Hope in the Fight against Alzheimer’s Dementia: Clinical Trial Systematic Review

  2024cited by this paper
• Crocin nano-chitosan-coated compound improves anxiety disorders, learning, and spatial memory in Alzheimer’s model induced by beta-amyloid in rats

  2024cited by this paper
• Biosynthesis of Nanoparticles with Green Tea for Inhibition of β-Amyloid Fibrillation Coupled with Ligands Analysis

  2024cited by this paper
• Curcumin Improves Neurogenesis in Alzheimer’s Disease Mice via the Upregulation of Wnt/β-Catenin and BDNF

  2024cited by this paper
• Modulation of Oxidative Stress and Neuroinflammation by Cannabidiol (CBD): Promising Targets for the Treatment of Alzheimer’s Disease

  2024cited by this paper
• 2024 Alzheimer's disease facts and figures

  2024cited by this paper
• NLRP3 inflammasome signalling in Alzheimer's disease.

  2024cited by this paper
• Withania somnifera (L.) Dunal, a Potential Source of Phytochemicals for Treating Neurodegenerative Diseases: A Systematic Review

  2024cited by this paper
• Resveratrol: Protective Agent Against Alzheimer's Disease.

  2024cited by this paper
• Epigallocatechin-3-Gallate and Genistein for Decreasing Gut Dysbiosis, Inhibiting Inflammasomes, and Aiding Autophagy in Alzheimer’s Disease

  2024cited by this paper
• Current Updates on Nanotechnology-based Drug Delivery Platforms for Treating Alzheimer's with Herbal Drugs.

  2024cited by this paper
• A systematic study of molecular targets of cannabidiol in Alzheimer's disease

  2024cited by this paper
• Penetratin and Mannose-Functionalized Cannabidiol Lipid Nanoparticles Encapsulating the BDNF Gene Reduce Amyloid-Induced Inflammation.

  2024influential reference
• Exploring the anti-inflammatory effects of curcumin encapsulated within ferritin nanocages: a comprehensive in vivo and in vitro study in Alzheimer’s disease

  2024cited by this paper
• High-intensity interval training combined with cannabidiol supplementation improves cognitive impairment by regulating the expression of apolipoprotein E, presenilin-1, and glutamate proteins in a rat model of amyloid β-induced Alzheimer’s disease

  2024cited by this paper
• Identification of Cannabidiolic and Cannabigerolic Acids as MTDL AChE, BuChE, and BACE‐1 Inhibitors Against Alzheimer's Disease by In Silico, In Vitro, and In Vivo Studies

  2024cited by this paper
• Pharmacodynamic and Clinical Effects of Ginkgo Biloba Extract EGb 761 and Its Phytochemical Components in Alzheimer’s Disease

  2024cited by this paper
• Cannabidiol ameliorates cognitive decline in 5×FAD mouse model of Alzheimer’s disease through potentiating the function of extrasynaptic glycine receptors

  2024cited by this paper
• Facile synthesis of EGCG modified Au nanoparticles and their inhibitory effects on amyloid protein aggregation.

  2024cited by this paper
• Mannose-Functionalized Chitosan-Coated PLGA Nanoparticles for Brain-Targeted Codelivery of CBD and BDNF for the Treatment of Alzheimer's Disease.

  2024cited by this paper
• Development, Statistical Optimization, and Characterization of Resveratrol-Containing Solid Lipid Nanoparticles (SLNs) and Determination of the Efficacy in Reducing Neurodegenerative Symptoms Related to Alzheimer's Disease: In Vitro and In Vivo Study

  2024cited by this paper
• Saffron and its major constituents against neurodegenerative diseases: A mechanistic review.

  2024cited by this paper
• Zinc-Epigallocatechin-3-gallate Network-Coated Nanocomposites against the Pathogenesis of Amyloid-Beta.

  2023cited by this paper
• Evidence of Clinical Efficacy and Pharmacological Mechanisms of Resveratrol in the Treatment of Alzheimer’s Disease

  2023cited by this paper
• Assessing Cannabidiol as a Therapeutic Agent for Preventing and Alleviating Alzheimer’s Disease Neurodegeneration

  2023cited by this paper
• Functionalized Cerium Dioxide Nanoparticles with Antioxidative Neuroprotection for Alzheimer’s Disease

  2023cited by this paper
• The Main Therapeutic Applications of Cannabidiol (CBD) and Its Potential Effects on Aging with Respect to Alzheimer’s Disease

  2023cited by this paper
• Targeting NLRP3 inflammasome for neurodegenerative disorders

  2023cited by this paper
• Epigallocatechin Gallate: A Multifaceted Molecule for Neurological Disorders and Neurotropic Viral Infections.

  2023cited by this paper
• Alzheimer’s Disease and Green Tea: Epigallocatechin-3-Gallate as a Modulator of Inflammation and Oxidative Stress

  2023cited by this paper
• Ox-inflammasome involvement in neuroinflammation.

  2023cited by this paper
• The NLRP3 inflammasome: contributions to inflammation-related diseases

  2023cited by this paper
• Active constituents of saffron (Crocus sativus L.) and their prospects in treating neurodegenerative diseases (Review)

  2023cited by this paper
• Inflammatory Processes in Alzheimer’s Disease—Pathomechanism, Diagnosis and Treatment: A Review

  2023influential reference
• Resveratrol-loaded selenium/chitosan nano-flowers alleviate glucolipid metabolism disorder-associated cognitive impairment in Alzheimer's disease.

  2023cited by this paper
• Effectiveness and safety of ginkgo biloba preparations in the treatment of Alzheimer's disease: A systematic review and meta-analysis

  2023cited by this paper
• Effectiveness of epigallocatechin gallate nanoparticles on the in-vivo treatment of Alzheimer’s disease in a rat/mouse model: a systematic review

  2023cited by this paper
• Resveratrol-Selenium Nanoparticles Alleviate Neuroinflammation and Neurotoxicity in a Rat Model of Alzheimer’s Disease by Regulating Sirt1/miRNA-134/GSK3β Expression

  2022cited by this paper
• Can We Use Ginkgo biloba Extract to Treat Alzheimer’s Disease? Lessons from Preclinical and Clinical Studies

  2022cited by this paper
• Amyloidosis in Alzheimer’s Disease: Pathogeny, Etiology, and Related Therapeutic Directions

  2022cited by this paper
• Cannabidiol Enhances Microglial Beta-Amyloid Peptide Phagocytosis and Clearance via Vanilloid Family Type 2 Channel Activation

  2022cited by this paper
• Ameliorative effects of phytomedicines on Alzheimer's patients.

  2022cited by this paper
• Curcumin Scaffold as a Multifunctional Tool for Alzheimer’s Disease Research

  2022influential reference
• Microglia Phenotypes in Aging and Neurodegenerative Diseases

  2022cited by this paper
• Astrocytic and microglial cells as the modulators of neuroinflammation in Alzheimer’s disease

  2022influential reference
• Neuroinflammation in Alzheimer’s Disease: Current Progress in Molecular Signaling and Therapeutics

  2022influential reference
• Saffron as a promising therapy for diabetes and Alzheimer's disease: mechanistic insights

  2022cited by this paper
• A Combination Therapy of Urolithin A+EGCG Has Stronger Protective Effects than Single Drug Urolithin A in a Humanized Amyloid Beta Knockin Mice for Late-Onset Alzheimer’s Disease

  2022cited by this paper
• Anti-inflammatory and memory-enhancing properties of Chinese herbal extracts: The possible application in Alzheimer’s disease

  2022cited by this paper
• Pathophysiology of Alzheimer's Disease.

  2022cited by this paper
• Microglia and Alzheimer’s Disease

  2022cited by this paper
• Macromolecular nanoparticles to attenuate both reactive oxygen species and inflammatory damage for treating Alzheimer's disease

  2022cited by this paper
• Pyroptosis in Alzheimer’s disease: cell type-specific activation in microglia, astrocytes and neurons

  2022influential reference
• Withania somnifera (L.) Dunal (Ashwagandha); current understanding and future prospect as a potential drug candidate

  2022cited by this paper
• Cannabidiol Inhibits Tau Aggregation In Vitro

  2021cited by this paper
• The Use of Ginkgo Biloba L. as a Neuroprotective Agent in the Alzheimer’s Disease

  2021cited by this paper
• The Effect of Cannabidiol Coated by Nano-Chitosan on Learning and Memory, Hippocampal CB1 and CB2 Levels, and Amyloid Plaques in an Alzheimer’s Disease Rat Model

  2021cited by this paper
• Oral Administration of Resveratrol-Selenium-Peptide Nanocomposites Alleviates Alzheimer's Disease-like Pathogenesis by Inhibiting Aβ Aggregation and Regulating Gut Microbiota.

  2021cited by this paper
• Green Tea Polyphenol Epigallocatechin-Gallate in Amyloid Aggregation and Neurodegenerative Diseases

  2021cited by this paper
• PLGA-Based Curcumin Delivery System: An Interesting Therapeutic Approach in the Treatment of Alzheimer’s Disease

  2021cited by this paper
• Potential and Limits of Cannabinoids in Alzheimer’s Disease Therapy

  2021cited by this paper
• Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression

  2021cited by this paper
• Neuroprotective Herbs for the Management of Alzheimer’s Disease

  2021cited by this paper
• Prospects of Saffron and its Derivatives in Alzheimer's Disease.

  2021cited by this paper
• Crocus sativus L. (Saffron) in Alzheimer's disease treatment: bioactive effects on cognitive impairment.

  2021cited by this paper
• Brain‐targeted co‐delivery of β‐amyloid converting enzyme 1 shRNA and epigallocatechin‐3‐gallate by multifunctional nanocarriers for Alzheimer's disease treatment

  2020cited by this paper
• Impact of Cannabis-Based Medicine on Alzheimer's disease by Focusing on the Amyloid β- Modifications: A Systematic Study.

  2020cited by this paper
• Effects of saffron (Crocus sativus L.) on cognitive function. A systematic review of RCTs

  2020cited by this paper
• NLRP3 inflammasome as a novel therapeutic target for Alzheimer's disease.

  2020cited by this paper
• Impact of Natural Compounds on Neurodegenerative Disorders: From Preclinical to Pharmacotherapeutics

  2020cited by this paper
• Neuronal mitochondria-targeted therapy for Alzheimer’s disease by systemic delivery of resveratrol using dual-modified novel biomimetic nanosystems

  2020cited by this paper
• NLRP3 inflammasome as a novel therapeutic target for Alzheimer’s disease

  2020cited by this paper
• Curcumin in Health and Diseases: Alzheimer’s Disease and Curcumin Analogues, Derivatives, and Hybrids

  2020cited by this paper
• Research Progress on Alzheimer's Disease and Resveratrol

  2020cited by this paper
• Neuroprotective effects of resveratrol in Alzheimer's disease.

  2020cited by this paper
• New mechanism of neuroinflammation in Alzheimer's disease: The activation of NLRP3 inflammasome mediated by gut microbiota.

  2020cited by this paper
• Neuroprotective effects of resveratrol in Alzheimer rsquo s disease

  2020cited by this paper
• The pharmacological activity of epigallocatechin-3-gallate (EGCG) on Alzheimer's disease animal model: A systematic review.

  2020cited by this paper
• Crocus-derived compounds alter the aggregation pathway of Alzheimer’s Disease: associated beta amyloid protein

  2020cited by this paper
• Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes

  2020cited by this paper
• Resveratrol and Neuroprotection: Impact and Its Therapeutic Potential in Alzheimer's Disease

  2020cited by this paper
• The Microbiota–Gut–Brain Axis and Alzheimer’s Disease: Neuroinflammation Is to Blame?

  2020cited by this paper
• Alzheimer‘s disease: exploring nature’s ‘medicinal chest’ for new therapeutic agents

  2020cited by this paper

• No citing papers are available for this paper.